CD4 and acute lymphoblastic leukemia: The specific interaction of ALL with a subset of CD4+ T cells was confirmed by inhibition assays with their characteristic ligand, as expected GalNAc inhibited most of ALL-binding sites for CD4+ cells (Figure 1(b)).